Skip to main content

Table 3 Comparing VAHL characteristics between Vac-1 and Vac-2 groups

From: Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation

  All- Vac group (n = 266) Vac-1 group (n = 91) Vac-2 group (n = 175) Pv
Grading Grade 1 VAHL 96 (36.1%) 40 (44.0%) 56 (32.0%) 0.05
Grade 2 VAHL 112 (42.1%) 40 (44.0%) 72 (41.1%) 0.66
Grade 3 VAHL 32 (12.0%) 7 (7.7%) 25 (14.3%) 0.12
Grade 4 VAHL 26 (9.8%) 4 (4.4%) 22 (12.6%) 0.03
Location Axilla-level 1 264 (99.2%) 90 (98.9%) 174 (99.4%) >0.99
Axilla-level 2 100 (37.6%) 24 (26.4%) 76 (43.4%) 0.01
Axilla-level 3 35 (13.2%) 7 (7.7%) 28 (16.0%) 0.06
Axilla-interpectoral 39 (14.7%) 5 (5.5%) 34 (19.4%) <0.01
Supraclavicular 21 (7.9%) 5 (5.5%) 16 (9.1%) 0.30
Intensity SUVmax 2.63 (1.85–3.82) 2.40 (1.74–3.19) 2.76 (1.97–4.29) 0.01
Size Enlarged LN 37 (13.9%) 6 (6.6%) 31 (17.7%) 0.01
  Visible injection site 99 (37.2%) 21 (23.1%) 78 (44.6%) <0.01
  1. Categorical variables are reported as frequency and percentage; continuous variables are reported as median and IQR